AzTrials
AzTrials

Hepatocellular CarcinomaPhase 2LOST-BNCT05537402

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

A Phase 2 study testing Atezolizumab and bevacizumab and transarterial chemoembolization (TACE) or transarterial radioembolization (TARE in people with Hepatocellular Carcinoma, run by University of Texas Southwestern Medical Center at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this research study is to compare the effectiveness and safety of two standard of care treatments in people who have been diagnosed with hepatocellular carcinoma (HCC).This research study is being done to compare atezolizumab/bevacizumab to locoregional therapy with either transarterial… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hepatocellular Carcinoma
What is being tested?
Atezolizumab and bevacizumab and transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1 participants
Where
1 siteUnited States
Study dates
27 Sep 2023to 6 Jun 2025
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with confirmed HCC by imaging (LI-RADS 5) or histopathology
  • Treatment-naïve, liver localized (intermediate-stage), i.e., beyond Milan Criteria (one tumor ≤5 cm, or two to three tumors, each ≤3 cm) and not amenable to curative surgery, liver transplantation, or local ablation and no evidence of extrahepatic disease or vascular invasion.
  • Child Pugh class A
  • Age ≥18 years at time of screening
  • ECOG Performance Status 0 or 1
  • Patients with HBV infection, which is characterized by positive hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibodies (anti-HBcAb) with detectable HBV NA (≥10 IU/ml or above the limit of detection per local lab standard), must be treated with antiviral therapy, as per institutional practice. HBV antiviral therapy must be initiated prior to randomization and patients must remain on antiviral therapy for the study duration and for 6 months after the last dose of study medication.
Show all 28Show fewer
  • Patients who test positive for anti-hepatitis B core (HBc) with undetectable HBV DNA (<10 IU/ml or under the limit of detection per local lab standard) are not required to start antiviral therapy prior to randomization. These subjects will be tested at every cycle to monitor HBV DNA levels and initiate antiviral therapy if HBV DNA is detected (≥10 IU/ml or above the limit of detection per local lab standard). HBV DNA detectable subjects must initiate and remain on antiviral therapy for the study duration and for 6 months after the last dose of study medication.
  • Patients with HCV infection, defined by presence of detectable antibody or RNA, should have management of this disease per local institutional practice throughout the study.
  • At least 1 measurable intrahepatic lesion suitable for repeat assessments according to the following mRECIST criteria: • Liver lesions that show typical features of HCC on IV contrast-enhanced CT or MRI scans, ie, hypervascularity in the arterial phase with washout in the portal or the late venous phase
  • Viable, non-necrotic portion (arterial phase IV contrast-enhancing) that can be accurately measured at baseline as ≥10 mm in the longest diameter
  • Adequate organ and marrow function at enrollment as defined below:
  • Hemoglobin ≥9.0 g/dL Patients may be transfused to meet this criterion.
  • Absolute neutrophil count ≥1500/μL
  • Platelet count ≥75000/μL
  • Total bilirubin ≤3 × the upper limit of normal (ULN)
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN
  • Albumin ≥2.8 g/dL
  • Lymphocyte count ≥0.5 X 109/L (500/µL)
  • 2+ proteinuria or less urine dipstick reading or normal UA with less than 100 mg/dL protein
  • Calculated creatinine clearance (CL) ≥30 mL/min as determined by Cockcroft-Gault (using actual body weight) or 24-hour urine creatinine CL
  • For patients not receiving therapeutic anticoagulation: INR or aPTT ≤2 × ULN
  • Upper endoscopy to evaluate varices and risk of bleeding is required within one year prior to randomization
  • Negative HIV test at screening
  • All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for 6 months following completion of therapy. Women must refrain from donating eggs during this same period. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
  • Has not undergone a hysterectomy or bilateral oophorectomy; or
  • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  • Ability to understand and the willingness to sign a written informed consent.

Who cannot join

  • Chemotherapy, radiotherapy, or other cancer therapy within 3 months prior to starting study treatment.
  • Any prior immunotherapy for malignancy.
  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • Patients with infiltrative-type HCC
  • Definite macrovascular invasion or distant metastatic disease at randomization
  • Clinically significant ascites, requiring non-pharmacological intervention (e.g., paracentesis) to maintain control within past 6 months
Show all 59Show fewer
  • History of hepatic encephalopathy within past 6 months
  • Actively listed or under evaluation for liver transplantation
  • Prior bleeding event due to untreated or incompletely treated esophageal and/or gastric varices within 6 months prior to randomization
  • History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation).
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
  • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.
  • Active tuberculosis
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
  • Patients with indwelling catheters (e.g., PleurX®) are allowed.
  • Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN)
  • History or evidence upon physical or neurological examination of central nervous system dysfuction
  • Current or recent (< 10 days prior to initiation of study treatment) use of aspirin (> 325 mg/day), or clopidogrel (> 75 mg/day) Note: The use of full-dose oral or parenteral anticoagulants for therapeutic purpose is permitted as long as the INR and/or aPTT is within therapeutic limits (according to institution standards) within 7 days prior to initiation of study treatment and the patient has been on a stable dose of anticoagulants for ≥ 2 weeks prior to initiation of study treatment. Prophylactic use of anticoagulants is allowed. However, the use of direct oral anticoagulant therapies such as dabigatran (Pradaxa®) and rivaroxaban (Xarelto®) is not recommended due to bleeding risk.
  • History of leptomeningeal disease
  • Uncontrolled tumor-related pain. Patients requiring pain medication should be on stable regimen prior to study entry.
  • Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions: Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.
  • Patients with controlled Type 1 diabetes mellitus who are on an insulin are eligible for the study.
  • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
  • Rash must cover <10% of body surface area.
  • Disease is well controlled at baseline and requires only low-potency topical corticosteroids.
  • There is no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the 12 months prior to Day 1 of Cycle 1.
  • Systemic immunostimulatory agents (including, but not limited to, IFNs and IL-2) are prohibited within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment and during study treatment.
  • History of hypertensive crisis or hypertensive encephalopathy.
  • Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to randomization.
  • History of arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to randomization.
  • History of grade ≥4 venous thromboembolism.
  • Non-healing wound, active ulcer, or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require wound examinations every 3 weeks.
  • History of abdominal fistula or GI perforation, non-healed gastric ulcer that is refractory to treatment, or active GI bleeding within 6 months prior to enrollment.
  • History of grade ≥ 2 hemoptysis (defined as ≥ 2.5 mL of bright red blood per episode) within one month of screening
  • Core biopsy or other minor surgical procedure, excluding vascular access device, within 7 days prior to initiation of study treatment.
  • Surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to initiation of study treatment, or anticipation of need for major surgical procedure during the course of the study (Note: Biopsy and endoscopy are not considered surgery so would not be exclusion criteria)
  • Uncontrolled hypertension defined by a systolic pressure >150 mmHg or diastolic pressure >90 mmHg, with or without antihypertensive medication. Patients with initial blood pressure (BP) elevations are eligible if initiation or adjustment of antihypertensive medication lowers pressure to meet entry criteria.
  • History of allogeneic stem cell or organ transplantation
  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection (except for noted HBV or HCV as detailed above), symptomatic congestive heart failure, poorly controlled diabetes mellitus, unstable angina pectoris, uncontrolled cardiac arrhythmia, active Interstitial Lung Disease (ILD), serious chronic GI conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
  • History of another primary malignancy except for
  • Malignancy treated with curative intent and with no known active disease ≥1 year before randomization and of low potential risk for recurrence
  • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  • Adequately treated carcinoma in situ without evidence of disease
  • History of active primary immunodeficiency.
  • Patients co-infected with HBV and hepatitis D virus (HDV). (HBV infection is defined above; HDV positive infection is indicated by the presence of anti-HDV antibodies).
  • Treatment with a live, attenuated vaccine (e.g., FluMist®) within 4 weeks prior to Day 1 of Cycle 1, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab.
  • 43 Subjects must have recovered from prior treatment-related toxicities to grade 1 or baseline (excluding alopecia and clinically stable toxicities requiring ongoing medical management).
  • 44. Subjects may not be receiving any other investigational agents for the treatment of the cancer under study.
  • 45. History of allergic reactions attributed to compounds of similar chemical or biologic composition to atezolizumab or bevacizumab or other agents used in study.
  • 46. Subjects must not be pregnant or breastfeeding during the study treatment, or have the intention of becoming pregnant during the study treatment or within 6 months after the final dose of study treatment due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants. Women of childbearing potential must have a negative serum or urine pregnancy test result within 14 days prior to initiation of study treatment.
  • 47. Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-a agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:
  • Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study.
  • Patients who receive mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.
  • 48. History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins.
  • 49. Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab formulation.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas

    Dallas, Texas, 75390

Other trials in United States

About this study

Official title: Phase II Multi-center Randomized, Open-label, Trial of Atezolizumab and Bevacizumab vs Locoregional Therapy (Transarterial Chemoembozliation or Radioembolization) as First-line Therapy in Patients With Large Intermediate-stage Hepatocellular Carcinoma

The purpose of this research study is to compare the effectiveness and safety of two standard of care treatments in people who have been diagnosed with hepatocellular carcinoma (HCC).This research study is being done to compare atezolizumab/bevacizumab to locoregional therapy with either transarterial chemoembolization (TACE) or transarterial radioembolization (TARE).

Read the detailed description

To evaluate the efficacy and safety of atezolizumab and bevacizumab compared to locoregional therapy (TACE or TARE) in patients with intermediate-stage HCC. The primary outcome is progression-free survival, which will be compared between two arms using stratified log-rank tests, adjusting the effect of stratification variables between two study arms. Cox regression analysis will be done to see if there are significant differences in PFS, controlling for the effects of confounding variables between the two study arms.

Being tested
Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
Medical subject headings
Carcinoma, Hepatocellular

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Atezolizumab and bevacizumabDrug

    Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle and Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle

  • transarterial chemoembolization (TACE) or transarterial radioembolization (TARERadiation

    TACE cycles occur every 8 weeks +/- 7 days OR TARE cycles occur every 12 weeks +/- 7 days

Study groups in NCT05537402
Study groupRoleWhat they receive
Arm A: Atezolizumab and bevacizumabExperimentalAtezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle. Atezolizumab will be administered first followed by bevacizumab, with a minimum of 5 minutes between dosing.
Receives: Drug: Atezolizumab and bevacizumab
Arm B: Locoregional therapy with TACE or TAREActive comparatorPatients will undergo locoregional therapy with TACE or TARE per investigator preference. TACE will be administered every 8 +/- 4 weeks; TARE will be administered every 12 +/- 4 weeks. Proportion of patients being treated with TARE will be capped at 50% of cohort at a protocol level. After 50% cap is reached, patients randomized to Arm B will be treated with TACE.
Receives: Radiation: transarterial chemoembolization (TACE) or transarterial radioembolization (TARE

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression-free Survival

    Evaluate the efficacy of atezolizumab and bevacizumab compared to TACE or TARE as measured by progression-free survival after randomization. PFS is defined as time from randomization to death from any cause or radiologic tumor progression, according to investigator assessment per mRECIST (modified Response Evaluation Criteria in Solid Tumors ).

    Measured: Baseline until date of first observed disease progression or death, assessed up to 24 months

Secondary outcomes (5)

  1. Overall Response Rate

    To evaluate the efficacy of atezolizumab and bevacizumab compared to locoregional therapy with TACE or TARE as measured by ORR.

    ORR to be assessed using investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    Measured: Baseline until date of first observed disease progression or death, assessed up to 24 months

  2. Time to Treatment Failure

    To evaluate the efficacy of atezolizumab and bevacizumab compared to locoregional therapy with TACE or Time to treatment failure, defined as time to death or inability to provide allocated treatment (atezolizumab/bevacizumab for Arm A or TACE/TARE for Arm B). Failure of strategy can be based on loss of clinical benefit, unacceptability toxicity, liver function deterioration, or no longer applicable as determined by local tumor board.

    Measured: Baseline until date of first observed disease progression or death, assessed up to 24 months

  3. Overall Survival

    To evaluate the efficacy of atezolizumab and bevacizumab compared to locoregional therapy with TACE or TARE as measured by OS.

    Overall survival after randomization, defined as time from randomization to death from any cause

    Measured: Baseline until date of death, assessed up to 24 months

  4. Time to Deterioration of Liver Function

    Time to deterioration of liver function, defined as time from randomization to first clinically meaningful deterioration in liver function, as measured by Child Pugh and ALBI. Meaningful increases in Child Pugh will be defined as increase in Child Pugh score to 8 and meaningful increased changes in ALBI will be defined as an increase in ALBI grade (from grade 1 to 2 or grade 2 to 3).

    Measured: Randomization until first clinically meaningful deterioration in liver function, assessed up to 24 months

  5. Time to Deterioration of Quality of Life

    To evaluate health related quality of life scores of patients treated with atezolizumab and bevacizumab compared to locoregional therapy with TACE or TARE.

    Time to deterioration of quality of life, defined as time for randomization to first clinically meaningful deterioration of quality of life measured by EORTC QLQ-C30 and EORTC-QLQ-HCC18.

    Measured: Randomization to first clinically meaningful deterioration of quality of life, assessed up to 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Sep 2022
  2. Study start27 Sep 2023
  3. Primary completion6 Jun 2025
  4. Study completion6 Jun 2025

Why it stopped: The decision was made to close the study to enrollment due to poor overall accrual and the inability to meet the 31% overall enrollment goal.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Patients will be randomly assigned to one of two study arms: Arm A: Atezolizumab and bevacizumab or Arm B: Locoregional therapy with TACE or TARE as determined by local site. Randomization will occur on 1:1 ratio through permuted-block randomization method and will be stratified.
Masking
None (open label)
Enrolment
1 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05537402
Sponsor's protocol ID
STU-2022-0848
Acronym
LOST-B
Status last verified
May 2026
First submitted
9 Sep 2022
Last updated
18 Jun 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Atezolizumab and bevacizumab and transarterial chemoembolization (TACE) or transarterial radioembolization (TARE in people with Hepatocellular Carcinoma, run by University of Texas Southwestern Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 28 inclusion and 59 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 18 Jun 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression-free Survival (time frame: Baseline until date of first observed disease progression or death, assessed up to 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05537402.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in